Antimicrobial disposition in pulmonary epithelial lining fluid of horses, Part III. Cefquinome

Winther, Lotte; Baptiste, Keith E.; Friis, Christian

doi:10.1111/j.1365-2885.2010.01248.x

Cited by 27 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported terminal half life, clearance and Vss were respectively 2.4 ± 0.21 h, 0.11 ± 0.03 L/h.kg, 0.3 ± 0.5 L/kg and were very close to our values. The terminal elimination half-life of cefquinome is similar to values that were observed in piglet (Zhang et al, 2014), ducks (Liguo et al, 2011), rabbit (Hwang et al, 2011), and horses (Winther et al, 2011) in the range of (0.9–2.77 h) following IV administration. The volume of distribution at steady state was low which means that cefquinome was not as widely distributed as previously reported for piglet (Zhang et al, 2014), sheep (Uney et al, 2011), rabbits (Hwang et al, 2011), and horses (Winther et al, 2011) in the range (0.19–0.36 L/kg).…”

Section: Discussionsupporting

confidence: 80%

Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle

et al. 2015

View full text Add to dashboard Cite

Cefquinome is a fourth generation cephalosporin with antimicrobial activity against gram negative and gram positive bacterial species, including Staphylococcus aureus. The aim of our study was to observe the ex-vivo activity of cefquinome against Staphylococcus aureus strains by using bovine serum from intravenously treated cattle. Cefquinome kinetics were measured by liquid chromatography and UV detection. In vitro post antibiotic effects (PAEs) and mutant prevention concentrations were determined with S. aureus strain ATCC 12598. Cefquinome exhibited time-dependent killing and produced in vitro PAEs increasing with concentration and time of exposure. A pharmacokinetic-pharmacodynamic model was established to simulate the efficacy of cefquinome for different dosage regimens. A dosage of 2 mg/kg every 12 h for 3 days was expected to reach a bactericidal activity against S. aureus in case of septicemia.

show abstract

Section: Discussionsupporting

confidence: 80%

Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Another important PK/PD parameter to describe drug efficacy is the time during which the drug concentration exceeds the MIC ( T > MIC) [42]. It is generally recommended that T > MIC should be at least 50% of the dosage interval to ensure an optimal bactericidal effect [42, 43]. During the present study, to optimize the marbofloxacin dosage regimen, we also calculated the T > MIC at a dose of 2.50 mg/kg of body weight in pigs after i.v., i.m., and p.o.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin in Pig against Korean Local Isolates ofActinobacillus pleuropneumoniae

Hossain

Park

Jeong

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

The pharmacokinetics of marbofloxacin in pigs after intravenous (i.v.), intramuscular (i.m.), and peroral (p.o.) administration and pharmacokinetic/pharmacodynamic indices of this drug against Korean local isolates of Actinobacillus pleuropneumoniae were determined in this study. Marbofloxacin (2.50 mg/kg of body weight) was administered, and blood samples were collected with designated time intervals. Plasma-extracted marbofloxacin was injected into the LC-MS/MS system. The in vitro and ex vivo antibacterial activities of marbofloxacin were evaluated against 20 isolates of A. pleuropneumoniae. The mean peak plasma concentrations (Cmax) after i.v., i.m., and p.o administration were 2.60 ± 0.10, 2.59 ± 0.12, and 2.34 ± 0.12 µg/mL at 0.25 ± 0.00, 0.44 ± 0.10, and 1.58 ± 0.40 h, respectively. The area under the plasma concentration-time curves (AUC0–24) and elimination half-lives were 24.80 ± 0.90, 25.80 ± 1.40, and 23.40 ± 5.00 h·μg/mL and 8.60 ± 0.30, 12.80 ± 1.10, and 8.60 ± 0.00 h, for i.v., i.m., and p.o. administration, correspondingly. The AUC0–24/MICs of marbofloxacin after i.v., i.m., and p.o. administration were 253.86 ± 179.91, 264.1 ± 187.16, and 239.53 ± 169.75 h, respectively. The Cmax/MIC values were 26.58 ± 18.84, 26.48 ± 18.77, and 23.94 ± 16.97, and T>MICs were 42.80 ± 1.01, 36.40 ± 1.24, and 38.60 ± 1.18 h, after i.v., i.m., and p.o. administration, respectively. Thus, marbofloxacin dosage of 2.50 mg/kg of body weight by i.v., i.m., and p.o. administration with 24 h dosing interval will provide effective treatment for the infection of pig by A. pleuropneumonia.

show abstract

“…Previous studies have described the pharmacokinetics of CFQ following the i.v. administration of both single (0.5–2 mg/kg, Allan & Thomas, ; CVMP, ; 1 mg/kg, Winther et al ., ; 4.5 mg/kg, Smiet et al ., ) and multiple (a total of 3 doses of 1 mg/kg at 8‐h intervals and 2 doses of 1 mg/kg at 12‐h intervals; Smiet et al ., ) doses in horses. These studies have not reported adverse reactions of horses to CFQ.…”

Section: Discussionmentioning

confidence: 99%

Plasma and synovial fluid pharmacokinetics of cefquinome following the administration of multiple doses in horses

Üney

Altan

et al. 2016

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The plasma and synovial fluid pharmacokinetics and safety of cefquinome, a 2-amino-5-thiazolyl cephalosporin, were determined after multiple intravenous administrations in sixteen healthy horses. Cefquinome was administered to each horse through a slow i.v. injection over 20 min at 1, 2, 4, and 6 mg/kg (n = 4 horses per dose) every 12 h for 7 days (a total of 13 injections). Serial blood and synovial fluid samples were collected during the 12 h after the administration of the first and last doses and were analyzed by a high-performance liquid chromatography assay. The data were evaluated using noncompartmental pharmacokinetic analyses. The estimated plasma pharmacokinetic parameters were compared with the hypothetical minimum inhibitory concentration (MIC) values (0.125-2 μg/mL). The plasma and synovial fluid concentrations and area under the concentration-time curves (AUC) of cefquinome showed a dose-dependent increase. After a first dose of cefquinome, the ranges for the mean plasma half-life values (2.30-2.41 h), the mean residence time (1.77-2.25 h), the systemic clearance (158-241 mL/h/kg), and the volume of distribution at steady-state (355-431 mL/kg) were consistent across dose levels and similar to those observed after multiple doses. Cefquinome did not accumulate after multiple doses. Cefquinome penetrated the synovial fluid with AUC /AUC ratios ranging from 0.57 to 1.37 after first and thirteenth doses, respectively. Cefquinome is well tolerated, with no adverse effects. The percentage of time for which the plasma concentrations were above the MIC was >45% for bacteria, with MIC values of ≤0.25, ≤0.5, and ≤1 μg/mL after the administration of 1, 2, and 4 or 6 mg/kg doses of CFQ at 12-h intervals, respectively. Further studies are needed to determine the optimal dosage regimes in critically ill patients.

show abstract

Antimicrobial disposition in pulmonary epithelial lining fluid of horses, Part III. Cefquinome

Cited by 27 publications

References 17 publications

Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle

Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin in Pig against Korean Local Isolates ofActinobacillus pleuropneumoniae

Plasma and synovial fluid pharmacokinetics of cefquinome following the administration of multiple doses in horses

Contact Info

Product

Resources

About